Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Br J Gen Pract ; 72(725): e891-e898, 2022 12.
Article in English | MEDLINE | ID: covidwho-2284757

ABSTRACT

BACKGROUND: Individuals with vitamin B12 deficiency (including pernicious anaemia) often report being 'let down' or stigmatised by general practice systems and policy, and choose instead to self-medicate via injection; the association between this and perceptions of safe primary care in this group of people is unknown. AIM: To examine the association between self-medication for vitamin B12 deficiency and patient-reported safety in primary care. DESIGN AND SETTING: A UK cross-sectional online survey. METHOD: The survey consisted of the three components: demographics; the validated Primary Care Patient Measure of Safety; and questions about self-medication for vitamin B12 deficiency. Multivariable logistic regression analyses and thematic synthesis were undertaken. RESULTS: Responses from 1297 participants indicated 508 (39.2%) self-medicated via injection. Perceived primary care safety was low. Those who self-medicated via injection reported a significantly lower level of patient safety in primary care including adverse patient-related factors (odds ratio 0.82, 95% confidence interval = 0.73 to 0.92), and patients >34 years of age were significantly more likely to self-medicate via injection. Many reported that treatment under the guidance of a clinician was preferable to self-medication, but felt they had no other choice to regain quality of life. Almost half felt that the doctor did not always consider what they wanted for their care. CONCLUSION: To the authors' knowledge, this is the largest study to date examining patient safety and vitamin B12 deficiency. It found that four out of 10 patients with B12 deficiency self-medicate via injection. Patients who self-medicated perceived primary care as less safe. Providing patient-centred care and treating these patients with dignity and respect is a policy priority to reduce unsafe health behaviours.


Subject(s)
Vitamin B 12 Deficiency , Vitamin B 12 , Humans , Vitamin B 12/therapeutic use , Cross-Sectional Studies , Quality of Life , Patient Safety , Vitamin B 12 Deficiency/epidemiology , United Kingdom/epidemiology
2.
J Neurol ; 269(2): 577-582, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1303319

ABSTRACT

BACKGROUND: The recent lockdown due to the COVID-19 pandemic has been linked to a higher incidence of psychiatric manifestations and substance abuse. The recreative use of nitrous oxide is more and more widespread and neurological complications are frequent. METHODS: We report clinical characteristics and biological findings of five consecutive patients presenting to our tertiary care center between April 2020 and February 2021 with various neurological symptoms occurring after recent nitrous oxide abuse. RESULTS: Our patients presented with subacute combined degeneration of the spinal cord (4/5 patients) or with acute inflammatory demyelinating polyneuropathy (1/5 patients). No patient had reduced vitamin B-12 titer, but all had elevated blood levels of homocysteine and methylmalonic acid. This reflects the functional deficit in vitamin B-12 that can be linked to nitrous oxide consumption. After vitamin B-12 supplementation, clinical signs regressed at least partially in all 5 patients. CONCLUSION: We report an elevated incidence of neurological complications of nitrous oxide abuse occurring during the recent COVID-19 lockdown. Nitrous oxide abuse should be tracked down in patients presenting with compatible neurological symptoms and elevated homocysteinemia. Vitamin B-12 should be supplemented as soon as the diagnosis is made.


Subject(s)
COVID-19 , Vitamin B 12 Deficiency , Communicable Disease Control , Humans , Nitrous Oxide/adverse effects , Pandemics , SARS-CoV-2 , Vitamin B 12 , Vitamin B 12 Deficiency/chemically induced , Vitamin B 12 Deficiency/epidemiology
5.
Med Hypotheses ; 146: 110374, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-919591

ABSTRACT

COVID-19 exacts a disproportionate toll on both the elderly and those with diabetes; these patients are more likely to require costly intensive care, longer hospitalisation, and die from complications. Nations would thus find it extremely difficult to either lift or sustain socially, economically, and politically damaging restrictions that keep this group of people safe. Without a vaccine, there is thus an urgent need to identify potential modifiable risk factors which can help manage overall fatality or recovery rates. Case fatality rates are highly variable between (and even within) nations; nutritional differences have been proposed to account significantly for this disparity. Indeed, vitamin B12 deficiency is a common denominator between the elderly and those with diabetes. The question on hand thus lies on whether managing B12 deficiencies will impact COVID-19 fatality outcome or recovery rates. Herein, we review the latest evidence that shows that B12 deficiency associates in multiple areas very similar to where COVID-19 exerts its damaging effects: immunologically; microbiologically; haematologically; and through endothelial cell signalling-supporting the hypothesis that B12 deficiency is a potential modifiable risk factor in our fight against COVID-19.


Subject(s)
COVID-19/complications , Diabetes Complications/epidemiology , Vitamin B 12 Deficiency/complications , Aged , COVID-19/epidemiology , COVID-19/therapy , Comorbidity , Critical Care , Folic Acid Deficiency/complications , Folic Acid Deficiency/epidemiology , Gastrointestinal Microbiome , Homocysteine/metabolism , Humans , Models, Biological , Obesity/complications , Obesity/epidemiology , Pandemics , Risk Factors , SARS-CoV-2/pathogenicity , Severity of Illness Index , Vitamin B 12/therapeutic use , Vitamin B 12 Deficiency/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL